ReviewThe oncologist2017

Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.

Grainne M O'Kane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.